表纸
市场调查报告书

大肠炎:开发平台分析

Colitis - Pipeline Review, H1 2019

出版商 Global Markets Direct 商品编码 232843
出版日期 内容资讯 英文 117 Pages
订单完成后即时交付
价格
Back to Top
大肠炎:开发平台分析 Colitis - Pipeline Review, H1 2019
出版日期: 2019年02月01日内容资讯: 英文 117 Pages
简介

大肠炎是大肠的发炎,由病毒、寄生虫、食物中毒(细菌)等感染,有过去大肠的发炎性疾病(溃疡性大肠炎、克隆氏症 )、血流的不足(缺血性大肠炎)等各种原因。腹痛,腹胀,血便,发冷,脱水,腹泻,有发热等症状,非类固醇消炎剂(NSAID),皮质类固醇等治疗方法处于。

本报告以全球大肠炎治疗药的开发平台为主题,提供目前开发平台状况和最新趋势,药物简介,主要企业及开发中的产品检讨等,为您概述为以下内容。

目录

简介

  • 调查范围

大肠炎概要

治疗药的开发

  • 开发中产品;概要
  • 开发中产品;比较分析

各企业开发中的治疗药

大学/机关研究中的治疗药

开发中产品概况

  • 后期阶段的产品
  • 临床阶段的产品
  • 初期阶段的产品

在企业开发中的产品

大学/机关研究中的产品

开发治疗药的企业

  • Aerpio Therapeutics, Inc.
  • Ajinomoto制药
  • Akebia Therapeutics, Inc.
  • Amorepacific Corporation
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Dr. Falk Pharma GmbH
  • Galapagos NV
  • Immuron Limited
  • Innate Pharma S.A.
  • Peptinov SAS
  • Pfizer Inc.
  • Prokarium Limited
  • Protalix BioTherapeutics, Inc.
  • RDD Pharma Ltd.
  • Saniona AB
  • Synovo GmbH

治疗药的评估

  • 单剂产品
  • 各标的
  • 各作用机制
  • 各给药途径
  • 各分子类型

药物简介

  • AcTMP-1
  • AKB-4924
  • AKB-6899
  • AN-346
  • 肿瘤治疗用肝素酶阻碍抗体
  • 大肠炎治疗用抗体
  • 发炎性疾病、大肠炎治疗用TNF Alpha阻碍反义RNAi寡核甘酸
  • APY-0201
  • BC-1215
  • BMS-986104
  • budesonide
  • 困难肠梭菌、疫苗
  • CSY-0073
  • 发炎性疾病、大肠炎治疗用TRP 流通管道拮抗剂
  • etanercept biosimilar
  • filgotinib
  • IMM-124E
  • IPH-33
  • mesalamine
  • NK-007
  • PAC-14028
  • Peptide to Inhibit NFkB 大肠炎、肠炎治疗用
  • PF-06425090
  • PPV-06
  • RDD-2007
  • 克隆氏症、大肠炎治疗用 TNF-Alpha阻碍重组蛋白品质
  • 大肠炎治疗药
  • 大肠炎治疗用 Panx1阻碍合成肽
  • 大肠炎治疗用白细胞介素12/23标的疫苗
  • 大肠炎治疗用白细胞介素23标的疫苗
  • ZK-216348

最近的开发平台趋势

暂停中的计划

开发中止的产品

产品开发里程碑

  • 主要消息和新闻稿

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC11061IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H1 2019, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 24, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Colitis - Overview
  • Colitis - Therapeutics Development
  • Colitis - Therapeutics Assessment
  • Colitis - Companies Involved in Therapeutics Development
  • Colitis - Drug Profiles
  • Colitis - Dormant Projects
  • Colitis - Discontinued Products
  • Colitis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Colitis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Colitis - Pipeline by AlfaSigma SpA, H1 2019
  • Colitis - Pipeline by Apollo Endosurgery Inc, H1 2019
  • Colitis - Pipeline by Concenter BioPharma Silkim Ltd, H1 2019
  • Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2019
  • Colitis - Pipeline by enGene Inc, H1 2019
  • Colitis - Pipeline by Genfit SA, H1 2019
  • Colitis - Pipeline by Handa Pharmaceuticals LLC, H1 2019
  • Colitis - Pipeline by Immodulon Therapeutics Ltd, H1 2019
  • Colitis - Pipeline by Immuron Ltd, H1 2019
  • Colitis - Pipeline by Inflazome Ltd, H1 2019
  • Colitis - Pipeline by Nippon Kayaku Co Ltd, H1 2019
  • Colitis - Pipeline by Ogeda SA, H1 2019
  • Colitis - Pipeline by Principia Biopharma Inc, H1 2019
  • Colitis - Pipeline by Protagonist Therapeutics Inc, H1 2019
  • Colitis - Pipeline by RDD Pharma Ltd, H1 2019
  • Colitis - Pipeline by Saniona AB, H1 2019
  • Colitis - Pipeline by Scholar Rock Inc, H1 2019
  • Colitis - Pipeline by Soligenix Inc, H1 2019
  • Colitis - Pipeline by Synthetic Biologics Inc, H1 2019
  • Colitis - Pipeline by Vitality Biopharma Inc, H1 2019
  • Colitis - Dormant Projects, H1 2019
  • Colitis - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Colitis - Dormant Projects, H1 2019 (Contd..2), H1 2019
  • Colitis - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Colitis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top